• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CavityPlus 2022 更新:一个集成平台,用于全面的蛋白质腔检测和性质分析,具有用户友好的工具和腔数据库。

CavityPlus 2022 Update: An Integrated Platform for Comprehensive Protein Cavity Detection and Property Analyses with User-friendly Tools and Cavity Databases.

机构信息

BMLMS, College of Chemistry and Molecular Engineering, Peking University, Beijing, PR China.

Center for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, PR China.

出版信息

J Mol Biol. 2023 Jul 15;435(14):168141. doi: 10.1016/j.jmb.2023.168141. Epub 2023 May 4.

DOI:10.1016/j.jmb.2023.168141
PMID:37356903
Abstract

Ligand binding sites provide essential information for uncovering protein functions and structure-based drug discovery. To facilitate cavity detection and property analysis process, we developed a comprehensive web server, CavityPlus in 2018. CavityPlus applies the CAVITY program to detect potential binding sites in a given protein structure. The CavPharmer, CorrSite, and CovCys tools can then be applied to generate receptor-based pharmacophore models, identify potential allosteric sites, or detect druggable cysteine residues for covalent drug design. While CavityPlus has been widely used, the constantly evolving knowledge and methods make it necessary to improve and extend its functions. This study presents a new version of CavityPlus, CavityPlus 2022 through a series of upgrades. We upgraded the CAVITY tool to greatly speed up cavity detection calculation. We optimized the CavPharmer tool for fast speed and more accurate results. We integrated the newly developed CorrSite2.0 into the CavityPlus 2022 web server for its improved performance of allosteric site prediction. We also added a new CavityMatch module for drug repurposing and protein function studies by searching similar cavities to a given cavity from pre-constructed cavity databases. The new version of CavityPlus is freely available at http://pkumdl.cn:8000/cavityplus/.

摘要

配体结合位点为揭示蛋白质功能和基于结构的药物发现提供了重要信息。为了促进腔检测和性质分析过程,我们于 2018 年开发了一个全面的网络服务器 CavityPlus。CavityPlus 应用 CAVITY 程序来检测给定蛋白质结构中的潜在结合位点。然后可以应用 CavPharmer、CorrSite 和 CovCys 工具来生成基于受体的药效团模型、识别潜在的变构位点或检测可共价设计药物的可成药性半胱氨酸残基。虽然 CavityPlus 已经得到了广泛的应用,但是不断发展的知识和方法使得有必要改进和扩展其功能。本研究通过一系列升级,介绍了 CavityPlus 的新版本 CavityPlus 2022。我们升级了 CAVITY 工具,大大加快了腔检测计算速度。我们优化了 CavPharmer 工具,以实现更快的速度和更准确的结果。我们将新开发的 CorrSite2.0 集成到 CavityPlus 2022 网络服务器中,以提高变构位点预测的性能。我们还添加了一个新的 CavityMatch 模块,用于通过从预先构建的腔数据库中搜索与给定腔相似的腔来进行药物再利用和蛋白质功能研究。新版本的 CavityPlus 可在 http://pkumdl.cn:8000/cavityplus/ 免费获得。

相似文献

1
CavityPlus 2022 Update: An Integrated Platform for Comprehensive Protein Cavity Detection and Property Analyses with User-friendly Tools and Cavity Databases.CavityPlus 2022 更新:一个集成平台,用于全面的蛋白质腔检测和性质分析,具有用户友好的工具和腔数据库。
J Mol Biol. 2023 Jul 15;435(14):168141. doi: 10.1016/j.jmb.2023.168141. Epub 2023 May 4.
2
CavityPlus: a web server for protein cavity detection with pharmacophore modelling, allosteric site identification and covalent ligand binding ability prediction.CavityPlus:一个用于蛋白质腔检测的网络服务器,具有药效团建模、别构位点识别和共价配体结合能力预测功能。
Nucleic Acids Res. 2018 Jul 2;46(W1):W374-W379. doi: 10.1093/nar/gky380.
3
Uncovering the Dominant Motion Modes of Allosteric Regulation Improves Allosteric Site Prediction.揭示别构调节的优势运动模式可提高别构结合位点预测。
J Chem Inf Model. 2022 Jan 10;62(1):187-195. doi: 10.1021/acs.jcim.1c01267. Epub 2021 Dec 29.
4
A web server for analysis, comparison and prediction of protein ligand binding sites.一个用于分析、比较和预测蛋白质配体结合位点的网络服务器。
Biol Direct. 2016 Mar 25;11(1):14. doi: 10.1186/s13062-016-0118-5.
5
CB-Dock: a web server for cavity detection-guided protein-ligand blind docking.CB-Dock:一个用于腔检测引导的蛋白质-配体盲目对接的网络服务器。
Acta Pharmacol Sin. 2020 Jan;41(1):138-144. doi: 10.1038/s41401-019-0228-6. Epub 2019 Jul 1.
6
PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database.PharmMapper 2017 更新:一个带有全面药物靶点药效数据库的潜在药物靶点识别网络服务器。
Nucleic Acids Res. 2017 Jul 3;45(W1):W356-W360. doi: 10.1093/nar/gkx374.
7
The visualCMAT: A web-server to select and interpret correlated mutations/co-evolving residues in protein families.可视化CMAT:一个用于选择和解释蛋白质家族中相关突变/共同进化残基的网络服务器。
J Bioinform Comput Biol. 2018 Apr;16(2):1840005. doi: 10.1142/S021972001840005X. Epub 2017 Dec 28.
8
NRIMD, a Web Server for Analyzing Protein Allosteric Interactions Based on Molecular Dynamics Simulation.NRIMD,一个基于分子动力学模拟分析蛋白质别构相互作用的网络服务器。
J Chem Inf Model. 2024 Oct 14;64(19):7176-7183. doi: 10.1021/acs.jcim.4c00783. Epub 2024 Jul 11.
9
MolHyb: A Web Server for Structure-Based Drug Design by Molecular Hybridization.MolHyb:基于分子杂交的结构导向药物设计的网络服务器。
J Chem Inf Model. 2022 Jun 27;62(12):2916-2922. doi: 10.1021/acs.jcim.2c00443. Epub 2022 Jun 13.
10
PDTD: a web-accessible protein database for drug target identification.PDTD:一个可通过网络访问的用于药物靶点识别的蛋白质数据库。
BMC Bioinformatics. 2008 Feb 19;9:104. doi: 10.1186/1471-2105-9-104.

引用本文的文献

1
Discovery of an allosteric 14-3-3 inhibitor for suppressing NRF2-driven cancer phenotypic screening and chemoproteomic-based target deconvolution.发现一种变构14-3-3抑制剂以抑制NRF2驱动的癌症:表型筛选和基于化学蛋白质组学的靶点反卷积
Chem Sci. 2025 Aug 20. doi: 10.1039/d5sc04324g.
2
Efficient Characterization of GPCRs Allosteric Modulation: Application to the Rational Design of De Novo S1PR1 Allosteric Modulators.G蛋白偶联受体变构调节的高效表征:在从头设计S1PR1变构调节剂的合理设计中的应用。
J Chem Inf Model. 2025 Aug 25;65(16):8637-8652. doi: 10.1021/acs.jcim.5c01163. Epub 2025 Aug 4.
3
Discovery of an autoinhibited conformation in mesotrypsin reveals a strategy for selective serine protease inhibition.
在中胰蛋白酶中发现自抑制构象揭示了一种选择性抑制丝氨酸蛋白酶的策略。
Sci Adv. 2025 Jul 4;11(27):eadu9129. doi: 10.1126/sciadv.adu9129.
4
A gain-of-function mutation in ATP6V0A4 drives primary distal renal tubular alkalosis with enhanced V-ATPase activity.ATP6V0A4中的功能获得性突变通过增强V-ATP酶活性导致原发性远端肾小管酸中毒。
J Clin Invest. 2025 Apr 29;135(13). doi: 10.1172/JCI188807. eCollection 2025 Jul 1.
5
The Arg108Cys Variant of Methylmalonyl-CoA Mutase: Clinical Implications for the Mexican Population Based on Molecular Dynamics and Docking.甲基丙二酰辅酶A变位酶的Arg108Cys变体:基于分子动力学和对接的墨西哥人群临床意义
Int J Mol Sci. 2025 Mar 22;26(7):2887. doi: 10.3390/ijms26072887.
6
Identification of ANKRD22 as a Theragnostic Target for Pancreatic Cancer and Fostamatinib's Therapeutic Potential.鉴定ANKRD22作为胰腺癌的治疗诊断靶点及 fostamatinib 的治疗潜力。
Int J Med Sci. 2025 Mar 19;22(8):1885-1904. doi: 10.7150/ijms.105193. eCollection 2025.
7
Anti-Butterfly Effect in Ribavirin Studied by Combined Experiment (PXRD/H-N NQR Cross-Relaxation Spectroscopy), Quantum Chemical Calculations, Molecular Docking, Molecular Dynamics Simulations, and Novel Structure-Binding Strength and Quadrupolar Indices.通过联合实验(粉末X射线衍射/氢-氮核磁共振交叉弛豫光谱)、量子化学计算、分子对接、分子动力学模拟以及新型结构结合强度和四极指数研究利巴韦林的反蝴蝶效应
Molecules. 2025 Feb 27;30(5):1096. doi: 10.3390/molecules30051096.
8
A BAG-1-inhibitory peptide, GO-Pep, suppresses c-Raf activity in cancer.一种BAG-1抑制肽GO-Pep可抑制癌症中的c-Raf活性。
Commun Biol. 2025 Feb 28;8(1):336. doi: 10.1038/s42003-024-07419-4.
9
Computer-aided drug repurposing & discovery for Hepatitis B capsid protein.用于乙肝衣壳蛋白的计算机辅助药物重新利用与发现
In Silico Pharmacol. 2025 Feb 25;13(1):35. doi: 10.1007/s40203-025-00314-8. eCollection 2025.
10
Covalent-Allosteric Inhibitors: Do We Get the Best of Both Worlds?共价变构抑制剂:我们能否两全其美?
J Med Chem. 2025 Feb 27;68(4):4040-4052. doi: 10.1021/acs.jmedchem.4c02760. Epub 2025 Feb 12.